Navigation Links
Continued Recognition for Excellence; Accelovance Named 2011 "Best CRO"
Date:4/18/2011

ROCKVILLE, Md., April 18, 2011 /PRNewswire-USNewswire/ -- Accelovance, a privately held clinical research company has been named the "Best Contract Research Organization (CRO)" for a third consecutive year. The World Vaccine Congress, held last week at the Gaylord National Hotel and Convention Center, Washington, D.C., hosted its annual Vaccine Industry Excellence (ViE) Awards to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry over the past 12 months.

"Recognition from our colleagues and clients at this level is truly an honor. I believe consistency in performance, value and partnership is what defines our company's success," said Stephen J. Trevisan, President and CEO.

The "Best CRO" category is designed to highlight the importance of contract research services within the vaccine industry; Accelovance has won the award three of the four years it has been a finalist. An international panel of judges evaluates category finalists on quality of work, range of services, strength of client relationships and performance.

"Quality and commitment are what define our organization," remarked Lee Barsky, Vice President of CRO Services. "It is equally rewarding to see how our diverse service offering helps Sponsors maintain growth despite challenging times in the industry."

Accelovance supports the business needs of biotech and small/mid pharma companies with cost-effective, flexible solutions that extend beyond traditional CRO services. Recently, the balanced perspective of study management and site operations positioned Accelovance to successfully rescue two Phase III therapeutic vaccine programs. Additionally, several Phase I vaccine studies in support of novel manufacturing or delivery methods are currently underway.

Headquartered in Rockville, Maryland, Accelovance has developed a unique operational approach for delivering quality, on time,
'/>"/>

SOURCE Accelovance
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
2. DSM Biomedical Announces Continued Partnership with Spinelab
3. HSC Trial Shows Continued Significant Hair Growth at One Year Follow-up
4. Continued Demand Makes Monsanto and Agriculture Unique Investment Opportunities, Global Seeds and Traits Lead to Tell Investors
5. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
6. GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
7. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
8. Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan
9. New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements
10. Avid Bioservices Expands Executive Team as it Prepares for Continued Growth
11. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Human Albumin Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The human albumin market analysis is provided ...
(Date:9/18/2014)...  U.S. biotech company Kultevat has strengthened ... technology developed by the Donald Danforth Plant Science ... for applications in production of natural rubber in ... developed under the direction of Roger Beachy , ... of the Danforth Plant Science Center, and is used ...
(Date:9/18/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... but separate underwritten offerings of 10,000,000 shares of its ... $2.00 per share, for expected gross proceeds of $20 ... Preferred Stock at a price to the public of ... million. Each share of Series A Convertible Preferred Stock ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... Stereotaxis, Inc. (Nasdaq:, STXS ) announced today ... quarter and full year ended December 31, 2008, on ... will host a conference call and,webcast on Thursday, February ... Company,s fourth quarter results and current corporate developments. The,dial-in ...
... Pharmaceuticals, Inc., a privately held drug development company, ... New Drug (IND) application with the U.S. Food ... anticancer compound. GGTI-2418 is a synthetic peptidomimetic ... to induce apoptosis by downregulating several pivotal oncogenic ...
... Ltd. (Nasdaq: XTLB , TASE: XTL) today ... a letter from a shareholder who,owns more than 5% ... an extraordinary shareholders, meeting (EGM) of the Company as,soon ... , 1. that Boaz Shweiger ...
Cached Biology Technology:Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter 2
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... to acquire and creatively manipulate spoken language is unique ... past 6 million years of human evolution to make ... best candidate gene we now have," says Wolfgang Enard, ... his efforts to understand the molecular biological basis of ... The results of his latest study, undertaken in collaboration ...
(Date:9/18/2014)... seem to be cheerful, happy-go-lucky characters, so you might ... life. , In fact some dogs are distinctly ... Sydney shows. , "This research is exciting because ... objectively and non-invasively. It offers researchers and dog owners ... that changes," said Dr Melissa Starling, from the Faculty ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... in French . , Montreal, December ... from a blueprint, Stephen Michnick is helping the scientific ... Universit de Montral biochemistry professor and Canada Research Chair ... that have enabled him to examine how proteins interact ...
... 16, 2008) Researchers from Virginia Commonwealth University have identified ... and suppress a key protein that is overexpressed in 90 ... to an effective gene therapy for cancer. According ... the Department of Human and Molecular Genetics and director of ...
... European Society of Oncological Urology (ESOU) will be ... January 2009, with organisers presenting the latest updates ... the fast-changing developments in onco-urological treatment strategies, the ... and researchers the opportunity to explore the various ...
Cached Biology News:Call Stephen Michnick a gene grammarian 2Researchers identify new anti-tumor gene 26th ESOU Meeting 2
...
... Protein, 1. Based on the methodology ... kit gives essentially colorless backgrounds in ... Protein provides convenient, reproducible and sensitive ... in less than two hours.The visualization ...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
Cyno macaque plasma and serum - various quantities available...
Biology Products: